Medline (MDLN) Competitors

$38.90 +0.19 (+0.49%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$39.05 +0.15 (+0.39%)

As of 05/14/2026 07:52 PM Eastern

MDLN vs. GEHC, PHG, ZBH, SNN, and PEN

Should you buy Medline stock or one of its competitors? MarketBeat compares Medline with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medline include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), and Penumbra (PEN). These companies are all part of the "medical equipment" industry.

How does Medline compare to GE HealthCare Technologies?

Medline (NASDAQ:MDLN) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Medline currently has a consensus price target of $50.85, indicating a potential upside of 30.71%. GE HealthCare Technologies has a consensus price target of $80.67, indicating a potential upside of 28.72%. Given Medline's stronger consensus rating and higher possible upside, equities analysts clearly believe Medline is more favorable than GE HealthCare Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	0 Sell rating(s)	6 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.86
GE HealthCare Technologies	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

In the previous week, GE HealthCare Technologies had 8 more articles in the media than Medline. MarketBeat recorded 13 mentions for GE HealthCare Technologies and 5 mentions for Medline. GE HealthCare Technologies' average media sentiment score of 1.07 beat Medline's score of 0.33 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GE HealthCare Technologies	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GE HealthCare Technologies has a net margin of 9.10% compared to Medline's net margin of 0.00%. GE HealthCare Technologies' return on equity of 20.46% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
GE HealthCare Technologies	9.10%	20.46%	5.73%

GE HealthCare Technologies has lower revenue, but higher earnings than Medline.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.80	N/A	N/A	N/A
GE HealthCare Technologies	$20.63B	1.38	$2.08B	$4.18	14.99

82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

GE HealthCare Technologies beats Medline on 7 of the 13 factors compared between the two stocks.

How does Medline compare to Koninklijke Philips?

Medline (NASDAQ:MDLN) and Koninklijke Philips (NYSE:PHG) are both large-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Medline currently has a consensus price target of $50.85, indicating a potential upside of 30.71%. Given Medline's stronger consensus rating and higher possible upside, equities analysts clearly believe Medline is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	0 Sell rating(s)	6 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.86
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Medline had 1 more articles in the media than Koninklijke Philips. MarketBeat recorded 5 mentions for Medline and 4 mentions for Koninklijke Philips. Medline's average media sentiment score of 0.33 beat Koninklijke Philips' score of 0.33 indicating that Medline is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Koninklijke Philips	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Koninklijke Philips has a net margin of 5.49% compared to Medline's net margin of 0.00%. Koninklijke Philips' return on equity of 13.51% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Koninklijke Philips	5.49%	13.51%	5.48%

Koninklijke Philips has lower revenue, but higher earnings than Medline.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.80	N/A	N/A	N/A
Koninklijke Philips	$20.17B	1.22	$1.01B	$1.17	21.81

13.7% of Koninklijke Philips shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Medline beats Koninklijke Philips on 8 of the 12 factors compared between the two stocks.

How does Medline compare to Zimmer Biomet?

Medline (NASDAQ:MDLN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

88.9% of Zimmer Biomet shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Zimmer Biomet had 6 more articles in the media than Medline. MarketBeat recorded 11 mentions for Zimmer Biomet and 5 mentions for Medline. Zimmer Biomet's average media sentiment score of 0.76 beat Medline's score of 0.33 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zimmer Biomet	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet has a net margin of 9.05% compared to Medline's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Zimmer Biomet	9.05%	13.24%	7.28%

Medline currently has a consensus price target of $50.85, indicating a potential upside of 30.71%. Zimmer Biomet has a consensus price target of $102.80, indicating a potential upside of 24.29%. Given Medline's stronger consensus rating and higher probable upside, research analysts clearly believe Medline is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	0 Sell rating(s)	6 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.86
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Zimmer Biomet has lower revenue, but higher earnings than Medline.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.80	N/A	N/A	N/A
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.48

Summary

Zimmer Biomet beats Medline on 8 of the 13 factors compared between the two stocks.

How does Medline compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Medline (NASDAQ:MDLN) are both large-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, Medline had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 5 mentions for Medline and 2 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 0.34 beat Medline's score of 0.33 indicating that Smith & Nephew SNATS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medline	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Smith & Nephew SNATS has higher earnings, but lower revenue than Medline.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.06	$625M	N/A	N/A
Medline	$28.43B	1.80	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Medline	N/A	N/A	N/A

Smith & Nephew SNATS presently has a consensus price target of $30.93, suggesting a potential upside of 4.11%. Medline has a consensus price target of $50.85, suggesting a potential upside of 30.71%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40
Medline	0 Sell rating(s)	6 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.86

25.6% of Smith & Nephew SNATS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Medline beats Smith & Nephew SNATS on 6 of the 10 factors compared between the two stocks.

How does Medline compare to Penumbra?

Penumbra (NYSE:PEN) and Medline (NASDAQ:MDLN) are both large-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

In the previous week, Medline had 1 more articles in the media than Penumbra. MarketBeat recorded 5 mentions for Medline and 4 mentions for Penumbra. Medline's average media sentiment score of 0.33 beat Penumbra's score of 0.25 indicating that Medline is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medline	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Penumbra has higher earnings, but lower revenue than Medline.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.06	$177.69M	$4.34	74.54
Medline	$28.43B	1.80	N/A	N/A	N/A

Penumbra has a net margin of 11.76% compared to Medline's net margin of 0.00%. Penumbra's return on equity of 10.87% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
Medline	N/A	N/A	N/A

Penumbra presently has a consensus price target of $361.33, suggesting a potential upside of 11.70%. Medline has a consensus price target of $50.85, suggesting a potential upside of 30.71%. Given Medline's stronger consensus rating and higher possible upside, analysts clearly believe Medline is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Medline	0 Sell rating(s)	6 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.86

88.9% of Penumbra shares are held by institutional investors. 2.9% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Medline beats Penumbra on 7 of the 13 factors compared between the two stocks.

Get Medline News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDLN vs. The Competition

Export

Metric	Medline	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$50.85B	$3.34B	$4.28B	$12.38B
Dividend Yield	N/A	N/A	6.42%	5.35%
P/E Ratio	N/A	3.23	22.80	25.63
Price / Sales	1.80	360.67	158.78	76.62
Price / Cash	N/A	4.36	53.46	56.33
Price / Book	N/A	3.92	36.80	6.97
Net Income	N/A	-$76.79M	$113.55M	$333.62M
7 Day Performance	-1.57%	-0.12%	2.85%	1.09%
1 Month Performance	-18.84%	-3.99%	5.01%	3.08%
1 Year Performance	N/A	55.03%	15.70%	35.68%

Medline Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDLN Medline	4.2551 of 5 stars	$38.90 +0.5%	$50.85 +30.7%	N/A	$50.85B	$28.43B	N/A	43,000	Positive News Analyst Forecast
GEHC GE HealthCare Technologies	4.953 of 5 stars	$61.79 +0.1%	$80.67 +30.5%	-14.0%	$28.07B	$20.98B	14.76	54,000	Insider Trade
PHG Koninklijke Philips	2.6234 of 5 stars	$27.50 +1.0%	N/A	+6.9%	$26.49B	$17.83B	25.95	65,340
ZBH Zimmer Biomet	4.5353 of 5 stars	$83.65 +1.0%	$102.80 +22.9%	-13.1%	$16.18B	$8.23B	21.72	17,000	Positive News
SNN Smith & Nephew SNATS	2.6038 of 5 stars	$30.20 -0.2%	$34.75 +15.1%	+6.0%	$12.88B	$6.16B	N/A	16,988

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDLN) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medline (MDLN) Competitors

MDLN vs. GEHC, PHG, ZBH, SNN, and PEN

How does Medline compare to GE HealthCare Technologies?

Summary

How does Medline compare to Koninklijke Philips?

Summary

How does Medline compare to Zimmer Biomet?

Summary

How does Medline compare to Smith & Nephew SNATS?

Summary

How does Medline compare to Penumbra?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDLN vs. The Competition

Medline Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medline (MDLN) Competitors

MDLN vs. GEHC, PHG, ZBH, SNN, and PEN

How does Medline compare to GE HealthCare Technologies?

Do analysts rate MDLN or GEHC?

Does the media favor MDLN or GEHC?

Is MDLN or GEHC more profitable?

Which has preferable valuation & earnings, MDLN or GEHC?

Do insiders and institutionals have more ownership in MDLN or GEHC?

Summary

How does Medline compare to Koninklijke Philips?

Do analysts rate MDLN or PHG?

Does the media favor MDLN or PHG?

Is MDLN or PHG more profitable?

Which has preferable valuation & earnings, MDLN or PHG?

Do insiders and institutionals have more ownership in MDLN or PHG?

Summary

How does Medline compare to Zimmer Biomet?

Do institutionals and insiders have more ownership in MDLN or ZBH?

Does the media prefer MDLN or ZBH?

Is MDLN or ZBH more profitable?

Do analysts rate MDLN or ZBH?

Which has better valuation and earnings, MDLN or ZBH?

Summary

How does Medline compare to Smith & Nephew SNATS?

Does the media refer more to SNN or MDLN?

Which has stronger earnings & valuation, SNN or MDLN?

Is SNN or MDLN more profitable?

Do analysts prefer SNN or MDLN?

Do insiders & institutionals hold more shares of SNN or MDLN?

Summary

How does Medline compare to Penumbra?

Does the media favor PEN or MDLN?

Which has preferable earnings and valuation, PEN or MDLN?

Is PEN or MDLN more profitable?

Do analysts prefer PEN or MDLN?

Do institutionals & insiders hold more shares of PEN or MDLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDLN vs. The Competition

Medline Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools